Drug class
Autologous CD34+ haematopoietic stem-cell gene therapy; lentiviral WAS gene addition product
Mechanism of action
Autologous CD34+ cells are transduced ex vivo with a lentiviral vector carrying functional WAS complementary DNA. Reinfused gene-modified stem cells engraft and generate haematopoietic progeny expressing WAS protein, addressing the underlying Wiskott-Aldrich syndrome gene defect.
General use cases
- Treatment of paediatric patients aged 6 months and older and adults with Wiskott-Aldrich syndrome caused by a WAS gene mutation, for whom HSCT is appropriate and no suitable HLA-matched related donor is available
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
